source
- Pfizer grants Medicus co-development rights to CD228-targeted ADC PF-08046031Pfizer announced it is transferring co-development rights for its CD228-targeted antibody-drug conjugate, PF-08046031, to Medicus Pharma. The ADC, originally discovered by Seagen, will now be adva…
- AstraZeneca and Ionis gene silencer Wainua fails trial after patients also took Pfizer heart drugAt the ESC Congress in Munich, a high‑profile trial of the gene‑silencing therapy Wainua, developed by AstraZeneca and Ionis, was reported to have failed. The failure was linked to participants co…